Oligonucleotide-based medicines (OBMs) have the potential to interrupt and reverse a huge range of genetic diseases, but there are too many possible OBMs to conduct safety and toxicity screening using old-fashioned trial-and-error approaches. Creyon takes a combined in vivo, in vitro, and in silico approach to solving that problem. The company knows how its library of survey compounds affects mammalian organs and whether they’re effective in patient cells; using this information, it has trained machine-learning algorithms to predict whether novel OBMs will have toxic or immune-stimulating effects.
First Investment: 2020
Deep Tech Opportunities Report